FDA granted accelerated approval for Regeneron's drug, which is expected for MM cases in the US in 2025.
1 report, 0 independent
Updated Jul 3
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA granted accelerated approval for Regeneron's drug, which is expected for MM cases in the US in 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
- FDA
Related events
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- FDA approval enables commercial availability for a product associated with Indianapolis.
- FDA approval expands patient access to therapies for ACCORD.
- FDA approved a new cancer drug in Massachusetts on October 21, 2026.
Coverage
Newest first; wire copies grouped- Unknown outlet